FOUNDED IN 2010
Dramatic advances in the biotechnology sector are creating an unprecedented opportunity to translate scientific breakthroughs into transformative medicines.
Aquilo Capital invests in drug development companies that harness the power of cutting-edge science to address urgent medical needs. We employ deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. In our view, these investment opportunities offer both substantial risk-adjusted returns as well as paradigm-changing therapeutics for patients and for society.
Focus on Biotech Stocks with Specific Characteristics: Aquilo does not invest in single product companies with potential binary outcomes based on clinical trials. Rather, we begin with a 1,200 stock universe of smaller cap biotechnology companies to find 10-15 with the following characteristics: 1) a diverse current pipeline of drugs; 2) partnerships with large pharma to reduce risk and development costs; 3) strong cash positions; 4) an innovative platform that will spur future developments. Stocks that are trading at a significant discount to intrinsic value are long candidates.
Focus on Less Efficient Stocks: Aquilo focuses on small-cap biotech companies in North America and Europe. Their universe is less efficient, as it is not well covered by either the buy or sell sides. The valuation discount for European based biotech provides an additional opportunity.